PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Octagon Research Solutions, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

INO Therapeutics Selects Octagon to Provide a Foundation for Their eCTD Capability Strategy - Chairman and CEO Jim Walker of Octagon Research Solutions, Inc., INO Therapeutics has selected Octagon’s StartingPoint®, eCTD JumpStart™ and ViewPoint® eCTD Complete solutions to launch their eCTD submission capabilities
INO Therapeutics Selects Octagon to Provide a Foundation for Their eCTD Capability Strategy

 

NewswireToday - /newswire/ - Wayne, PA, United States, 2007/02/20 - Chairman and CEO Jim Walker of Octagon Research Solutions, Inc., INO Therapeutics has selected Octagon’s StartingPoint®, eCTD JumpStart™ and ViewPoint® eCTD Complete solutions to launch their eCTD submission capabilities.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Company Chooses Three of Octagon’s Integrated, Cross-functional Solutions.

Chairman and CEO Jim Walker of Octagon Research Solutions, Inc., a pioneer and leader in the electronic transformation of clinical R&D in the life sciences industry, today announced that INO Therapeutics has selected Octagon’s StartingPoint®, eCTD JumpStart™ and ViewPoint®) eCTD Complete solutions to launch their eCTD submission capabilities.

StartingPoint is a global eCTD template suite that supports eCTD document authoring. eCTD JumpStart is a collection of standards and best practices supported by expert services that provide a foundation for eCTD submission processes. Finally, ViewPoint eCTD Complete is a technology solution that pairs Octagon’s innovative technologies with expert support services to provide core submission capabilities including compilation, issue management, viewing and validation.

Richard Bourne, vice president of Regulatory Affairs at INO Therapeutics, LLC., noted, “We are developing a strong foundation for becoming eCTD-ready. The solutions we chose complement our current capabilities and provide practical guidance on eCTD throughout the submission process.”

In recent months, the U.S. Food and Drug Administration has announced a change to a proposed rule and conducted a Part 15 Public Meeting on the topic of electronic submissions, eCTD and electronic data.

“We understand the shifts in the regulatory landscape and we are proactively preparing our organization to transition to eCTD. This is a strategic priority for our company, “added Bourne. “We chose Octagon’s solutions because they understand the business requirements surrounding submission development and their solutions clearly demonstrate that practical knowledge.”

Jim Walker, chairman and CEO added, “As we follow the recent agency activities around electronic submissions and electronic data, we see that implementing eCTD is becoming a priority for many competitive organizations in our industry. We look forward to providing progressive companies like INO Therapeutics with a full suite of integrated solutions that support efficient eCTD processes and reach across their organization to provide recurring value to their R&D professionals.”

About Octagon Research Solutions, Inc.
Octagon is a pioneer and leading process-centric solutions provider that offers a suite of regulatory, clinical, process, and IT solutions to the life sciences industry. Octagon synchronizes processes and increases automation to reduce island-to-island inefficiencies within the clinical research and development process. We leverage the power of electronic submissions through deep domain knowledge, cross-functional electronic submission expertise, a holistic process approach, and integrated solutions. Octagon is headquartered in Wayne, PA, with European headquarters in Amersham, UK.

About INO Therapeutics, Inc.
INO Therapeutics is a multi-national specialty pharmaceutical company, with core competencies in development of late stage drugs and marketing of pharmaceuticals and delivery devices. We are committed to research and development focused on meeting unmet medical needs in critical care medicine.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Octagon Research Solutions, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


INO Therapeutics Selects Octagon to Provide a Foundation for Their eCTD Capability Strategy

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Jim Graham - OctagonResearch.com 
610-535-6500 x5655 jgraham[.]octagonresearch.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Octagon Research Solutions, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Octagon Research Solutions, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  NAKIVO, Inc.





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)